Loading…
TARA
Protara Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$3.82-4.26%
Key metrics
- Market cap
- $225.74M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.4x
- Dividend yield
- —
- EPS
- -$1.36
- ROE
- -45.80%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.49
- 52-week high
- $7.82
- 52-week low
- $3.02
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
- 46
- New York, United States
Company description provided by Yahoo Finance.